Back to Search Start Over

Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin/tazobactam or meropenem from the MERINO study

Authors :
Scott A. Beatson
David Looke
Mesut Yilmaz
David C. Lye
Ka Lip Chew
Marco Falcone
Leah W. Roberts
Ahmed Zikri
Matteo Bassetti
Amy Crowe
A Henderson
Graeme R. Nimmo
Elda Righi
Michelle J Bauer
Genevieve Walls
Hasan Bhally
Raymond T. P. Lin
Nick Daneman
Yaseen M. Arabi
Paul A. Tambyah
Naomi Runnegar
Tiffany Harris-Brown
David L. Paterson
Thamer H. Alenazi
R Cakmak
Souha S. Kanj
Tau Hong Lee
K Chaw
Jon Iredell
M Ai Khamis
Anton Y. Peleg
Spiros Miyakis
Rogers Ba
Eugene Athan
Paul M. Griffin
Mark D. Chatfield
Partha Pratim De
Kyra Cottrell
Tom H. Boyles
Paul R. Ingram
Merino Trial Investigators
Patrick N A Harris
Marc Mendelson
Mo Yin
E. Tan
Publication Year :
2021
Publisher :
Oxford University Press, 2021.

Abstract

Introduction This study aims to assess the association of piperacillin/tazobactam and meropenem minimum inhibitory concentration (MIC) and beta-lactam resistance genes with mortality in the MERINO trial. Methods Blood culture isolates from enrolled patients were tested by broth microdilution and whole genome sequencing at a central laboratory. Multivariate logistic regression was performed to account for confounders. Absolute risk increase for 30-day mortality between treatment groups was calculated for the primary analysis (PA) and the microbiologic assessable (MA) populations. Results In total, 320 isolates from 379 enrolled patients were available with susceptibility to piperacillin/tazobactam 94% and meropenem 100%. The piperacillin/tazobactam nonsusceptible breakpoint (MIC >16 mg/L) best predicted 30-day mortality after accounting for confounders (odds ratio 14.9, 95% confidence interval [CI] 2.8–87.2). The absolute risk increase for 30-day mortality for patients treated with piperacillin/tazobactam compared with meropenem was 9% (95% CI 3%–15%) and 8% (95% CI 2%–15%) for the original PA population and the post hoc MA populations, which reduced to 5% (95% CI −1% to 10%) after excluding strains with piperacillin/tazobactam MIC values >16 mg/L. Isolates coharboring extended spectrum β-lactamase (ESBL) and OXA-1 genes were associated with elevated piperacillin/tazobactam MICs and the highest risk increase in 30-day mortality of 14% (95% CI 2%–28%). Conclusions After excluding nonsusceptible strains, the 30-day mortality difference from the MERINO trial was less pronounced for piperacillin/tazobactam. Poor reliability in susceptibility testing performance for piperacillin/tazobactam and the high prevalence of OXA coharboring ESBLs suggests that meropenem remains the preferred choice for definitive treatment of ceftriaxone nonsusceptible Escherichia coli and Klebsiella.

Details

Language :
English
Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....1beaa9ae6f053be65cfd8c244a65656b